438.51MMarket Cap-3785P/E (TTM)
6.600High6.010Low2.55MVolume6.400Open6.330Pre Close15.72MTurnover3.61%Turnover RatioLossP/E (Static)71.07MShares14.84052wk High2.88P/B435.30MFloat Cap2.09052wk Low--Dividend TTM70.55MShs Float978.000Historical High--Div YieldTTM9.32%Amplitude-1731.000Historical Low6.176Avg Price1Lot Size
Altimmune Stock Forum
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet